The FDA hearing addressing regulatory requirements for leadless pacemakers took up a number of issues associated with a device type that has been available in Europe for nearly three years now. Despite the extensive experience in other national jurisdictions, the advisory committee recommended that the agency not allow device makers to enroll patients from their pivotal studies into post-approval studies, which would require a new enrollment of more than 1,700 patients for each device.